Shots:
- The NMPA has approved Enstilar (calcipotriene/betamethasone dipropionate) for the treatment of adult patients with plaque psoriasis in China. Following NMPA approval, Enstilar is planned to launch in China later this year
- NMPA approval was backed by a P-III trial (n=604) in Chinese adults with plaque psoriasis, where QD Enstilar showed superior efficacy and met 1EPs and 2EPs vs Daivobet ointment
- Enstilar is an aerosol foam for the treatment of adult psoriasis vulgaris, used for up to 4 weeks, with responders eligible for long-term maintenance
Ref: LEO Pharma | Image: LEO Pharma | Press Release
Related News: LEO Pharma Reports the US FDA’s sNDA Acceptance of Anzupgo for Use in Children with Chronic Hand Eczema
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
